Commission amends Ontario Power Generation's operating licence for the Darlington Nuclear Generating Station to authorize the production of lutetium-177 and yttrium-90
May 26 2025 - Ottawa
Today, the Canadian Nuclear Safety Commission (CNSC) announced the Commission's decision to amend Ontario Power Generation's (OPG) power reactor operating licence for the Darlington Nuclear Generating Station (NGS) to authorize the production of lutetium-177 (Lu-177) and yttrium-90 (Y-90) using the existing target delivery system on Darlington NGS Unit 2. This decision follows a public hearing in writing with interventions. The amended licence remains valid until November 30, 2025.
The Darlington NGS is located in the Municipality of Clarington, Ontario, within the traditional lands and waters of the Michi Saagiig Anishinaabeg, the Gunshot Treaty (1787-88), the Williams Treaties (1923), and the Williams Treaties Settlement Agreement (2018).
In making its decision, the Commission considered written submissions from OPG, CNSC staff and 7 intervenors. After reviewing all submissions, the Commission concluded that OPG is qualified to carry on the activities that the amended licence will authorize.
The record of decision is available upon request by contacting the Commission Registry at interventions@cnsc-ccsn.gc.ca. It will also be posted in both official languages on the CNSC website at cnsc-ccsn.gc.ca at a later date. All submissions are also available on the CNSC website.
The CNSC regulates the use of nuclear energy and materials to protect health, safety, security and the environment; to implement Canada's international commitments on the peaceful use of nuclear energy; and to disseminate objective scientific, technical and regulatory information to the public. The Commission is a quasi-judicial administrative tribunal set up at arm's length from government, independent from any political, government or private sector influence.
Quick facts
Lu-177 and Y-90 are radioactive isotopes that are used in nuclear medicine, most prominently for targeted radionuclide therapy of certain types of cancer.
The Commission is satisfied with the regulatory hold point proposed by CNSC staff to verify aspects of the safety case, including confirmation via commissioning tests, prior to declaring the new isotope production available for service.
Related links
Contact
Media Relations Canadian Nuclear Safety Commission
Tel: 613-996-6860
Email: media@cnsc-ccsn.gc.ca
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a day ago
- Cision Canada
STATEMENT FROM THE NATIONAL COUNCIL FOR RECONCILIATION ON THE 10TH ANNIVERSARY OF THE RELEASE OF THE TRUTH AND RECONCILIATION COMMISSION'S CALLS TO ACTION Français
OTTAWA, ON, June 4, 2025 /CNW/ - Today marks the 10th Anniversary of the Truth and Reconciliation Commissions Calls to Action, which were released alongside their summary final report. The National Council for Reconciliation honours the Commission for its work, listening to Indian Residential School Survivors, their families, community members and affected Canadians in establishing these important calls for action to advance reconciliation. The National Council for Reconciliation was recently established. We commit the Council to further the important work of reconciliation. With the opportunity to witness the 10 years since the release of the Calls to Action, we recognize the importance of reminding governments and all Canadians to re-double their efforts to implement the Calls to Action. We also call on Canadians to see where reconciliation has occurred across the country, and to follow these examples. Reconciliation is instrumental in realizing renewed relationships between Indigenous and other peoples in Canada. Edith Cloutier, the Chair of the National Council for Reconciliation stated: "10 years on from the release of the Commission's Calls to Action, our work as a National Council for Reconciliation begins. This accentuates the fact that much work remains, and we will be here to celebrate and to document the work that is being done. We call on all Canadians, all levels of government and all sectors of society to remain committed to advancing reconciliation." The Council recognizes that progress has been made. However much more is needed. Reconciliation is not just about repairing the past; it's about creating a better future for Indigenous people and a better future for Canada.
Cision Canada
28-05-2025
- Cision Canada
Laurentis Energy Partners set to produce two powerful cancer-fighting isotopes
With regulatory approval secured, OPG's Darlington reactors will become single largest source of isotope production in North America TORONTO, May 28, 2025 /CNW/ - Cancer patients around the world could soon benefit from improved access to potentially life-saving treatments generated by the production of two critical medical isotopes – Yttrium-90 (Y-90) and Lutetium-177 (Lu-177) – at Ontario Power Generation's (OPG) Darlington Nuclear Generating Station. The Canadian Nuclear Safety Commission has approved a licence amendment that allows OPG subsidiary Laurentis Energy Partners (Laurentis) to begin producing the isotopes in Darlington's CANDU nuclear reactors. These isotopes are part of a new wave of targeted radionuclide therapies that deliver radiation directly to cancer cells while sparing healthy tissue, offering new hope to patients with hard-to-treat cancers such as liver, neuroendocrine, and prostate. Demand for these isotopes is growing rapidly as new treatments are developed and approved in global markets. Darlington's CANDU design enables production of medical isotopes without interrupting electricity generation, ensuring a steady, reliable supply. The isotopes are produced using Laurentis's proprietary isotope irradiation system, developed in partnership with BWXT Medical Ltd. and installed on Unit 2 at Darlington. The system is the single largest isotope production system in North America. When production begins, Darlington will become a key commercial power reactor source of Y-90 and Lu-177 globally. Key facts: This expansion builds on Laurentis's production of Molybdenum-99 at Darlington, the first commercial nuclear station in the world licensed to produce the isotope. Its decay product, Technetium-99m, is used in over 30 million diagnostic procedures annually. In 2024, the first Ontario patient was treated with publicly funded Lu-177-based therapy for prostate cancer. Laurentis could produce enough Lu-177 at Darlington to supply nearly 3 million doses, enough to fully treat 500,000 patients annually and vastly increase the global supply capacity. Once irradiated, Y-90 will be sent to BWXT Medical's facility in Kanata, Ontario, to be packaged into Boston Scientific's TheraSphere® Y-90 Glass Microspheres and distributed to over 30 countries globally. Commercial production of Y-90 is anticipated to begin in 2026, while commercial production of Lu-177 is expected to begin in 2027. Quotes: "For the first time, Ontario will be producing these critical medical isotopes at Darlington's CANDU nuclear reactors. This is leadership as Ontario advances its nuclear advantage, while saving lives for the thousands of Canadians diagnosed with cancer each year," said Stephen Lecce, Ontario's Minister of Energy and Mines. "Protecting Ontario starts with protecting our people. The production of cancer-fighting isotopes at Darlington shows how our world-class nuclear sector is delivering real benefits to people—creating high-skilled jobs, driving innovation, and save lives." "Our government is giving people access to more treatment options by expanding public access to life-saving medications and treatments," said Sylvia Jones, Ontario's Deputy Premier and Minister of Health. "This vital expansion of medical isotope production is another way we are spearheading Ontario-made innovation and connecting more people to world-class cancer care for years to come." "Darlington Nuclear Generating Station is not only helping power Ontario's growing clean energy needs; it is also powering the future of cancer care," said Nicolle Butcher, OPG President and CEO. "The isotopes produced at Darlington will have real-world impact for cancer patients around the world." "For patients and families waiting for new treatment options, this is a moment of real hope," said Jason Van Wart, Laurentis President and CEO. "We're proud to lead Canada's growing role in nuclear medicine, and even prouder to know that our work will directly support life-saving care for patients around the world." About Laurentis Energy Partners Laurentis Energy Partners, a subsidiary of OPG, is a global leader in the production of life-saving medical isotopes. From advanced cancer therapies to diagnostic imaging, Laurentis is helping power the future of nuclear medicine. The company also leverages its access to decades of nuclear knowledge and experience to deliver specialized nuclear services that include small modular reactor development, CANDU refurbishment, inspections, engineering, nuclear byproduct management, and decommissioning support globally. Laurentis has offices in the Greater Toronto Area, Hamilton, and Bruce County in Ontario, Saint John in New Brunswick, Regina in Saskatchewan, and Bucharest and Cernavoda in Romania. Follow us on Twitter/X or LinkedIn or visit
Canada Standard
27-05-2025
- Canada Standard
Commission amends Ontario Power Generation's operating licence for the Darlington Nuclear Generating Station to authorize the production of lutetium-177 and yttrium-90
May 26 2025 - Ottawa Today, the Canadian Nuclear Safety Commission (CNSC) announced the Commission's decision to amend Ontario Power Generation's (OPG) power reactor operating licence for the Darlington Nuclear Generating Station (NGS) to authorize the production of lutetium-177 (Lu-177) and yttrium-90 (Y-90) using the existing target delivery system on Darlington NGS Unit 2. This decision follows a public hearing in writing with interventions. The amended licence remains valid until November 30, 2025. The Darlington NGS is located in the Municipality of Clarington, Ontario, within the traditional lands and waters of the Michi Saagiig Anishinaabeg, the Gunshot Treaty (1787-88), the Williams Treaties (1923), and the Williams Treaties Settlement Agreement (2018). In making its decision, the Commission considered written submissions from OPG, CNSC staff and 7 intervenors. After reviewing all submissions, the Commission concluded that OPG is qualified to carry on the activities that the amended licence will authorize. The record of decision is available upon request by contacting the Commission Registry at interventions@ It will also be posted in both official languages on the CNSC website at at a later date. All submissions are also available on the CNSC website. The CNSC regulates the use of nuclear energy and materials to protect health, safety, security and the environment; to implement Canada's international commitments on the peaceful use of nuclear energy; and to disseminate objective scientific, technical and regulatory information to the public. The Commission is a quasi-judicial administrative tribunal set up at arm's length from government, independent from any political, government or private sector influence. Quick facts Lu-177 and Y-90 are radioactive isotopes that are used in nuclear medicine, most prominently for targeted radionuclide therapy of certain types of cancer. The Commission is satisfied with the regulatory hold point proposed by CNSC staff to verify aspects of the safety case, including confirmation via commissioning tests, prior to declaring the new isotope production available for service. Related links Contact Media Relations Canadian Nuclear Safety Commission Tel: 613-996-6860 Email: media@
